01.12.2012 Views

behavioral neurology and neuropsychiatry fellowship

behavioral neurology and neuropsychiatry fellowship

behavioral neurology and neuropsychiatry fellowship

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

CURRICULUM VITAE<br />

Name: Eugene Lai<br />

Degree(s) MD PhD Year of Birth<br />

Medical School Baylor College of Medicine Date of Graduation 1986<br />

Certification(s) American Board of Psychiatry <strong>and</strong> Neurology<br />

ABPN-Psychiatry ( ) YES (X) NO Date<br />

ABPN-Neurology (X) YES ( ) NO Date<br />

ABPN-Child Neurology ( ) YES (X) NO Date<br />

ABPN-Other (specify) ( ) YES (X) NO Date<br />

Other Board ( ) YES (X) NO Date<br />

Other (name below) ( ) YES (X) NO Date<br />

List any equivalent training here:<br />

Date<br />

Active State Licensure(s):<br />

Texas<br />

Current Academic Positions:<br />

Professor of Neurology<br />

Director PADRECC<br />

Current Hospital Appointments:<br />

TMH, MEDVAMC<br />

Fellowship/post-graduate training (type & location):<br />

Date(s)<br />

1990-Present<br />

Date Assumed this Position<br />

2003-<br />

2001-<br />

Date of Appointments<br />

1990-Present<br />

Date of Completion<br />

In the space below, list the most recent publications in journals (maximum 10 articles).<br />

Do not include presentations, abstracts, <strong>and</strong> those ‘in preparation’ or ‘submitted.’<br />

CLINICAL INVESTIGATION EXPERIENCE<br />

1. Principal investigator, Prospective open-label study of the efficacy <strong>and</strong> safety<br />

of botulinum toxin A in the treatment of dystonia<br />

2. Principal investigator, A double-blind, placebo-controlled study of CEP-151<br />

(recombinant IGF-1) in the treatment of amyotrophic lateral sclerosis<br />

3. Co-investigator, A double-blind, placebo-controlled, parallel group, high-dose<br />

study of tacrine (CI-970) in patients with Alzheimer's disease<br />

4. Co-investigator, A multicenter, r<strong>and</strong>omized, double-blind, placebo-controlled<br />

evaluation of the safety <strong>and</strong> efficacy of E2020 in patients with Alzheimer's<br />

disease<br />

5. Co-investigator, The efficacy of controlled-release oral physostigmine in<br />

Alzheimer's disease <strong>and</strong> senile dementia of the Alzheimer type<br />

UCNS Program Accreditation Application<br />

Behavioral Neurology & Neuropsychiatry February 2006<br />

Page 26

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!